LMCG Investments’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

LMCG Investments’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-5,933	Closed	-$258K	–	303
2023 Q3	$258K	Buy	5,933 +130	+2%	+$4.64K	0.02%	280
2023 Q2	$210K	Hold	5,803	–	–	0.01%	286
2023 Q1	$216K	Buy	5,803 +135	+2%	+$6.07K	0.01%	292
2022 Q4	$257K	Buy	5,668 +12	+0.2%	+$777	0.02%	292
2022 Q3	$395K	Buy	5,656 +35	+0.6%	+$2.59K	0.03%	286
2022 Q2	$377K	Hold	5,621	–	–	0.03%	288
2022 Q1	$462K	Buy	+5,621	New	+$575K	0.03%	285

Other funds holding MRTX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Simplicity Solutions Minneapolis, Minnesota $3.66B AUM 23.51% 1-Year Est. Return

Braslyn New Providence, Bahamas $7.81M AUM 338.68% 1-Year Est. Return

LMCG Investments's MRTX Position: Q4 2023 in Review

LMCG Investments sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2023, closing a stake of 5,933 shares — an estimated $258K sold.

LMCG Investments first reported a position in MRTX in Q1 2022 and held it in 7 quarters. The position peaked at $462K in Q1 2022. 217 funds tracked by Wall St. Rank hold MRTX as of Q4 2023.

LMCG Investments reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
LMCG Investments sold 5,933 Mirati Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $258K.
LMCG Investments first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2022 and held it in 7 quarters.
LMCG Investments's Mirati Therapeutics, Inc. Common Stock position peaked at $462K in Q1 2022.
217 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2023.

Based on LMCG Investments's 13F filing for Q4 2023, filed 8 Feb 2024.